{"generic":"Hepatitis A Vaccine, Inactivated","drugs":["Havrix","Havrix Pediatric","Hepatitis A Vaccine, Inactivated","Vaqta","Vaqta Pediatric"],"mono":{"0":{"id":"jsens0","title":"Generic Names","mono":"Hepatitis A Vaccine, Inactivated"},"1":{"id":"jsens1","title":"Dosing and Indications","sub":{"0":{"id":"jsens1b4","title":"Adult Dosing","mono":"<ul><li><b>Hepatitis A; Prophylaxis:<\/b> (19 years or older) Vaqta(R), 1 mL (50 units) IM x 1 dose; booster dose of 1 mL (50 units) 6 to 18 months later<\/li><li><b>Hepatitis A; Prophylaxis:<\/b> Havrix(R), 1 mL (1440 ELISA units) IM x 1 dose; booster dose 6 to 12 months later<\/li><li><b>Hepatitis A; Prophylaxis:<\/b> (postexposure; healthy persons up to 40 years of age) single, age-appropriate vaccine dose as soon as possible after hepatitis A exposure<\/li><\/ul>"},"1":{"id":"jsens1b5","title":"Pediatric Dosing","mono":"<ul><li>safety and effectiveness not established in pediatric patients younger than 12 months<\/li><li><b>Hepatitis A; Prophylaxis:<\/b> (age 12 months through 18 years) Vaqta(R), pediatric\/adolescent formulation, 0.5 mL (25 units) IM x 1 dose; booster dose of 0.5 mL (25 units) 6 to 18 months later<\/li><li><b>Hepatitis A; Prophylaxis:<\/b> (age 12 months to 18 years) Havrix(R), 0.5 mL (720 ELISA units) IM x 1 dose; booster dose 6 to 12 months later<\/li><li><b>Hepatitis A; Prophylaxis:<\/b> (postexposure; healthy persons 12 months or older) single, age-appropriate vaccine dose as soon as possible after hepatitis A exposure<\/li><\/ul>"},"3":{"id":"jsens1b7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Hepatitis A; Prophylaxis<br\/>"}}},"3":{"id":"jsens3","title":"Contraindications\/Warnings","sub":[{"id":"jsens3b9","title":"Contraindications","mono":"severe allergic reaction (eg, anaphylaxis) after previous administration of any hepatitis A-containing vaccine or any component of the vaccine, including neomycin <br\/>"},{"id":"jsens3b10","title":"Precautions","mono":"<ul><li>acute illness with or without fever, moderate or severe; defer vaccination unless the benefit of protection outweighs the risk of an adverse reaction<\/li><li>hepatitis A infection, unrecognized, at time of vaccination; vaccine may not prevent infection (Vaqta(R))<\/li><li>immunocompromised patients, including those receiving immunosuppressive drugs; diminished immune response may occur<\/li><li>latex sensitivity; tip cap and rubber plunger of prefilled syringes may contain natural latex rubber; vial stopper may contain natural latex rubber<\/li><li>syncope, possibly accompanied by transient neurological signs (eg, visual disturbance, paresthesia, tonic-clonic limb movements), may occur (Havrix(R))<\/li><li>report suspected adverse events to the Vaccine Adverse Event Reporting System (VAERS) at 1-800-822-7967 or at www.vaers.hhs.gov<\/li><\/ul>"},{"id":"jsens3b11","title":"Pregnancy Category","mono":"<ul><li>C (FDA)<\/li><li>B2 (AUS)<\/li><\/ul>"},{"id":"jsens3b12","title":"Breast Feeding","mono":"Micromedex: Infant risk is minimal.<br\/>"}]},"4":{"id":"jsens4","title":"Drug Interactions","sub":{"1":{"id":"jsens4b14","title":"Major","mono":"<ul>Cyclosporine (theoretical)<\/ul>"}}},"5":{"id":"jsens5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Erythema (20% to 23.9%), Injection site induration (1% to 10%), Injection site pain (21% to 56%), Swelling (8.7% to 10.2%)<\/li><li><b>Gastrointestinal:<\/b>Loss of appetite (1% to 26.1%), Nausea (1% to 10%)<\/li><li><b>Neurologic:<\/b>Headache (less than 9% to 14%), Irritability (27.2% to 43.9%), Somnolence (20.8% to 35.3%)<\/li><li><b>Other:<\/b>Fatigue (1% to 10%), Fever (0.4% to 10%), Malaise (1% to 10%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Dermatologic:<\/b>Erythema multiforme<\/li><li><b>Hematologic:<\/b>Thrombocytopenia<\/li><li><b>Hepatic:<\/b>Hepatitis, Jaundice<\/li><li><b>Immunologic:<\/b>Anaphylactoid reaction, Anaphylaxis<\/li><li><b>Neurologic:<\/b>Encephalopathy, Guillain-Barr  syndrome, Seizure<\/li><li><b>Other:<\/b>Angioedema, Transfusion reaction due to serum protein reaction<\/li><\/ul>"},"6":{"id":"jsens6","title":"Drug Name Info","sub":{"0":{"id":"jsens6b17","title":"US Trade Names","mono":"<ul><li>Havrix<\/li><li>Havrix Pediatric<\/li><li>Vaqta<\/li><li>Vaqta Pediatric<\/li><\/ul>"},"2":{"id":"jsens6b19","title":"Class","mono":"Vaccine<br\/>"},"3":{"id":"jsens6b20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"jsens6b21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"jsens7","title":"Mechanism Of Action","mono":"Hepatitis A vaccine, inactivated is a noninfectious hepatitis A vaccine that is cultured in MRC(5) human diploid cells from the virus (strain HM175). It promotes immunization against infectious hepatitis A virus (HAV).<br\/>"},"9":{"id":"jsens9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/>IM use only; do not inject IV, subQ, or intradermally<br\/><\/li><li><b>Intramuscular<\/b><br\/><ul><li>shake well before use<\/li><li>preferred injection site is in the deltoid for patients older than 2 years or the anterolateral thigh in patients 12 to 23 months old<\/li><li>immune globulin, human, can be given concurrently with Vaqta(R); administer using different syringes at different injection sites<\/li><li>(adults) may receive typhoid Vi polysaccharide and yellow fever vaccines concurrently with Vaqta(R); administer with different syringes at different injection sites<\/li><li>(children) concurrently administered vaccines may include: measles, mumps, and rubella virus vaccine live; varicella vaccine live; diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed; measles, mumps, rubella, and varicella vaccine live; pneumococcal 7-valent conjugate vaccine (diphtheria CRM(197)); and haemophilus B conjugate vaccine (meningococcal protein conjugate); administer using different syringes at different injection sites<\/li><li>(children) Havrix(R) may be given concurrently with Haemophilus influenzae type b (Hib) conjugate vaccine (PRP-T) in children 15 to 18 months of age, the fourth dose of pneumococcal 7-valent conjugate vaccine in children 15 months of age, and immune globulin; administer with different syringes at different injection sites<\/li><\/ul><\/li><\/ul>"},"11":{"id":"jsens11","title":"How Supplied","mono":"<ul><li><b>Havrix<\/b><br\/>Intramuscular Suspension: 1440 EL U\/ML<br\/><\/li><li><b>Havrix Pediatric<\/b><br\/>Intramuscular Suspension: 720 EL U\/0.5 ML<br\/><\/li><li><b>Vaqta<\/b><br\/><ul><li>Intramuscular Solution: 50 U\/ML<\/li><li>Intramuscular Suspension: 50 U\/ML<\/li><\/ul><\/li><li><b>Vaqta Pediatric<\/b><br\/>Intramuscular Suspension: 25 U\/0.5 ML<br\/><\/li><\/ul>"},"13":{"id":"jsens13","title":"Clinical Teaching","mono":"<ul><li>Warn patient that the tip cap and plunger of the prefilled syringes contain dry natural latex rubber that may cause allergic reaction in patients with latex sensitivity.<\/li><li>Tell patient that drug may provide immunity to hepatitis A within 15 to 50 days, but will not treat active hepatitis or prevent infection with other types of hepatitis.<\/li><li>Drug may cause headache, irritability, drowsiness, loss of appetite, and injection-site soreness, pain, and redness.<\/li><li>Advise patient that a booster dose will be given 6 to 12 months after initial dose.<\/li><\/ul>"}}}